Podcasts about biomarin pharmaceutical

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Former executives of MyoKardia have launched a new biotech company called Kardigan with $300 million in funding, aiming to make cardiovascular disease curable and preventable. In other news, Pfizer's subcutaneous PD-1 blocker has shown success in a phase III trial for bladder cancer, potentially providing a new treatment option. Lilly has partnered with venture capital firm Andreessen Horowitz on a $500 million fund for early-stage biotech companies. However, the Healey ALS trial involving Denali Therapeutics, AbbVie, and Calico Life Sciences has faced setbacks, highlighting challenges in developing treatments for amyotrophic lateral sclerosis. Updates in the biopharma industry include Lilly's investments in IPF treatments, rising costs of Part D drugs, and layoffs at companies like IGM Biosciences, Shoreline, and Intellia. Verdiva has entered the obesity market with a $410 million debut. Job opportunities in the biopharma sector include positions at Biomarin Pharmaceutical, Avidity Biosciences, AbbVie, and Moderna Inc.

Long time friends and industry colleagues, Lisa Chamberlain James with Trilogy and Cheryl Roberts with BioMarin Pharmaceutical sit down to discuss orphan drugs. They go over clinical trial hurdles, key incentives for health authorities, the medical writing process and start with an important question – why are orphan drugs called orphan drugs? Find out on episode 28 of TriloTalk!  

Twenty years of innovation in therapies targeting EGFR provides a case study in how generation of differentiated products against the target can drive market growth. On the latest BioCentury This Week podcast, BioCentury's editors discuss EGFR as a prime example of the value in best-in-class development strategies, with meaningful improvements across multiple modalities delivering substantial therapeutic benefits to patients. Analogous best-in-class opportunities aren't limited to cancer, but are also playing out in other settings such as immunology.The editors then discuss a recent event that hosted FDA commissioner Rob Califf and four former commissioners, all of whom agreed a major role of the FDA commissioner is to protect the agency from political interference. Washington Editor Steve Usdin also previews his conversation with FDA's Richard Pazdur, and Editor in Chief Simone Fishburn details takeaways from her Q&A with James Sabry, who recently became CBO at BioMarin Pharmaceutical.View full story: https://www.biocentury.com/article/65392600:00 - Introduction00:38 - EGFR Case Study08:45 - FDA Commissioners & Politics19:19 - James Sabry's TimelineTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Use AI to Speed up Your Work Flow Ethically and Securely. There are lots of courses on AI out there, but this one is specific only to medical writing and editing.  Access the AIMWE course waitlist. https://www.learnamastyle.com/waitlist/ Leqselvi for Alopecia Areata: The FDA has approved deuruxolitinib (Leqselvi) as a first-line treatment for adults with moderate to severe alopecia areata (AA). Developed by Sun Pharma, this oral selective inhibitor of Janus kinases JAK1 and JAK2 is typically dosed at 8 mg twice daily. The approval, based on the THRIVE-AA1 and THRIVE-AA2 trials, marks an important addition to limited treatment options for AA, which has significant psychological impacts. Femlyv Dissolvable Birth Control: The FDA has approved norethindrone acetate and ethinyl estradiol (Femlyv) as an oral dissolvable birth control pill, expanding access for those who have difficulty swallowing. This form of hormonal birth control, in use since 1968 as a swallowable tablet, also helps manage conditions like endometriosis and PMDD. The approval, based on a study of 743 women, offers a new option with common side effects like headache and nausea. Brineura for Batten Disease: The FDA has expanded the indication for cerliponase alfa (Brineura) to treat neuronal ceroid lipofuscinosis type 2 (CLN2 disease) in children under 3 years of age. Developed by BioMarin Pharmaceutical, this enzyme replacement therapy, initially approved in 2017, is administered by infusion into the brain. The expanded approval was based on a phase 2 trial showing reduced motor function decline and delayed disease onset. Erzofri for Schizophrenia: The FDA has approved paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia and schizoaffective disorder in adults. This long-acting injectable (LAI) antipsychotic, administered once a month, improves patient adherence by reducing dosing frequency. Developed by Luye Pharma Group, it was granted a U.S. patent in 2023 and approved under the 505(b)(2) pathway. Eque-cel for MS: The FDA has approved the IND application for equecabtagene autoleucel (Eque-cel) for treating multiple sclerosis (MS). Developed by IASO Biotechnology, this chimeric antigen receptor autologous T cell injection showed promising efficacy in six autoimmune diseases in a Chinese trial. MS, affecting 3.07 million people worldwide, is characterized by CNS demyelination and neuronal injury, with Eque-cel offering a new treatment option. Spravato for TRD: Johnson & Johnson has submitted an sNDA for esketamine (Spravato) as a monotherapy for adults with treatment-resistant depression (TRD). Already approved in combination with an oral antidepressant, esketamine is an NMDA receptor antagonist that rapidly alleviates depressive symptoms. The submission is based on Phase 4 TRD4005 study results, showing rapid improvement in depression scores with a consistent safety profile. ZW191 Anti-Tumor Agent: The FDA has cleared the IND application for ZW191, a novel antibody-drug conjugate (ADC) targeting folate receptor alpha (FR⍺) in cancers like gynecologic and NSCLC. Developed by Zymeworks, this TOPO1i ADC uses a novel payload, ZD06519, showing robust antitumor activity and a tolerable safety profile in preclinical models. Clinical development of ZW191 is planned to begin in the second half of 2024.

New data published today by LinkedIn, the world's largest professional network, has revealed that the role of software engineer is the top job for new graduates in Ireland, showing the strong demand for highly-skilled workers across the tech industry. This reflects a broader trend, with previous LinkedIn research revealing that demand for software engineers in Ireland outstrips supply, with a steady flow of talent coming into the country from places such as India, the UK, Brazil, Turkey and the Netherlands. The top three jobs for graduates are completed by audit associate in second place and quality control analyst in third spot. Accounting professionals remain highly in-demand with a raft of firms across the industry including the Big Four - KPMG, PwC, EY and Deloitte - hiring for these roles. The influence of Pharma, another of Ireland's big employers, can be seen in the rankings in the form of third-placed quality control analyst. Over the past 50 years, Ireland has become the EU's largest exporter of pharmaceuticals. The sector's impact on the Irish economy is also evident in the recent LinkedIn Top Companies Ireland list - 13 of the 25 featured are pharmaceutical companies, including BioMarin Pharmaceutical and AstraZeneca in the top two spots. Two-tier access to flexible work opportunities Another key highlight from LinkedIn's data highlights a two-tier system for the availability of flexible working for graduates compared to established professionals. Just over a quarter (26.7%) of entry-level job postings at the start of the year had hybrid/remote availability, but that contrasts to almost half (47.5%) for mid-senior level jobs. Some positions offer more flexibility for new grads, with software engineer (64.8%) coming out on top again with the most remote availability for hybrid or remote opportunities. Commenting on the data, Sue Duke, LinkedIn Ireland Country Manager, said: "Demand for highly-skilled software engineers in Ireland is sky high, and graduates with these specialist skills are experiencing a hiring boom. Our data and the IDA's recent Labour Market Pulse underscore the need to continue to cultivate a pipeline of tech talent to meet industry needs, accelerated by the growth of Generative AI. "Our analysis also shows a high level of competition among employers for these professionals, with greater work flexibility for entry-level software engineers compared to their graduate peers - where we see an overall trend towards significantly lower hybrid and remote work flexibility for entry-level jobs. This often reflects employers' desire to bolster their workplace culture and ensure that junior staff develop strong relationships with more senior colleagues, but it also poses the question about how companies should support the next generation of professionals in balancing work and life from the outset of their careers." Learning Opportunities LinkedIn is unlocking a range of LinkedIn Learning courses globally to help graduate job seekers gain skills to find their next opportunity. These include: Turning an internship into a job Job hunting for college grads Professional networking for career starters How to land job interviews without applying online The step-by-step guide to rock your job interview Negotiating your job offer and salary These courses are available for free from 29 May to 30 June. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us o...

Synopsis: In this episode of the Biotech 2050 podcast, host Rahul Chaturvedi engages in a thought-provoking conversation with Ray Stevens, a prominent figure in the biotech industry who co-founded Structure Therapeutics. Ray's extensive experience and pivotal role in advancing structure-based drug discovery make him a compelling guest for biotech entrepreneurs seeking to navigate the challenges of entrepreneurship and funding strategies. The episode delves into Ray's journey as a serial entrepreneur, the evolution of structure-based drug discovery, and the strategies employed by Structure Therapeutics to drive innovation and create impactful treatments for global health challenges. Ray's insights into the changing funding environment, the impact of distributed teams on value creation, and the significance of shared passion and mission in a company's success offer valuable knowledge for industry professionals and entrepreneurs. His reflections on the industry's future trends and the personal growth aspect add a relatable and human element to the discussion, making it a valuable resource for individuals at all career stages. Biography: Dr. Stevens helped pioneer the field of structure-based drug discovery. He has been involved in the discovery and development of several therapeutic molecules that have become breakthrough drugs including Palnziq™, which was developed at BioMarin Pharmaceutical and approved in 2018 to treat phenylketonuria. Dr. Stevens also founded Receptos which developed Zeposia™—a GPCR agonist targeting the S1PR1 receptor approved in 2020 for multiple sclerosis and 2021 for ulcerative colitis. Prior to Structure, Dr. Stevens founded the Bridge Institute at the University of Southern California (USC), and the iHuman Institute at ShanghaiTech University. He was previously a tenured chaired chemistry professor at Scripps Research and before that, an assistant professor of chemistry at the University of California, Berkeley. Dr. Stevens' laboratory and students have launched several successful biotech startups including Syrrx (acquired by Takeda), MemRx (acquired by Chiron/Novartis), Receptos (acquired by Celgene/BMS), and RuiYi (now Bird Rock Bio). A prolific scholar, Dr. Stevens has authored more than 400 peer-reviewed publications and received several academic and industry awards. Dr. Stevens conducted postdoctoral research in structural biology at Harvard University with William Lipscomb, who was awarded the Nobel Prize for Chemistry in 1976. Dr. Stevens earned his Ph.D. in chemistry from USC with Robert Bau and George Olah, the latter of whom received the Nobel Prize for Chemistry in 1994. He completed his undergraduate degree in chemistry from the University of Southern Maine.

Dr. Alejandro (Alex) Dorenbaum, M.D., is the Chief Medical Officer of Reneo Pharmaceuticals ( https://reneopharma.com/ ), a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases, including mitochondrial diseases, with significant unmet medical needs. Previously, Dr. Dorenbaum was Chief Medical Officer at Allakos, where he achieved proof-of-concept in clinical trials for novel therapeutic antibodies targeting inflammatory cells. He also served as Chief Medical Officer at Lumena Pharmaceuticals until its acquisition by Shire Pharmaceuticals. Prior to that, Dr. Dorenbaum worked at Genentech, where he was responsible for the respiratory programs for asthma and cystic fibrosis, and at BioMarin Pharmaceutical, where he conducted the clinical development of Kuvan. He began his career at Chiron Corporation, gaining broad expertise in several areas of drug development including biologics, small molecules and vaccines. Dr. Dorenbaum received his M.D. from the National Autonomous University in Mexico City. He completed his residency in pediatrics at University of Texas Health Science Center and held a fellowship in allergy and immunology at Baylor College of Medicine. He maintains an active academic position as Clinical Professor in Pediatrics at Stanford University School of Medicine, where he specializes in allergy and immunology. Support the show

I am so excited to have Dr. John Klock with me today! Dr. Klock is an internal medicine physician, board certified in hematology, oncology, and immunology. He is the reason you can have a virtual colonoscopy, the reason why you can have a calcium score, and he just continues to up the game. His overall goal is to make accurate imaging affordable and accessible for all and he started with breast imaging! Let's dive in!You will hear:The biggest problem in medicine todayWhat's wrong with mammogram and MRI screenings todayDr. Klock's mission to improve the types of imaging we have availableWhat QT imaging is and how it worksAnd so much more!More about Dr. Klock:Dr. Klock has served as Chief Executive Officer of QT Imaging since 2014 and as Managing Director, Manager and Founder of the Company since 2011. Prior to QT Imaging, Dr. Klock was involved in the start-up of five medical companies, including Co-Founder and President of BioMarin Pharmaceutical, which successfully commercialized five FDA approved drugs; Scientific Founder and Vice President of Research of Glycomed, now Ligand Pharmaceutical; and founding investor in Ultragenyx Pharmaceutical. He also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions. Dr. Klock has authored over 70 peer-reviewed medical and scientific publications, and eight granted patents.Connect with Dr. Klock:QT Imaging website: https://www.qtimaging.com/LinkedIn : https://www.linkedin.com/in/john-klock-151aa650To talk to a member of Dr. Jenn's team and learn more about working privately with RHMD, visit: https://calendly.com/stephanie-1031/time-to-talkTo get your copy of Dr. Jenn's book, The Smart Person's Guide to Breast Cancer, visit: https://realhealthmd.kartra.com/page/SmartPersonsGuidetoBreastCancerJoin the Facebook group: Facebook: https://www.facebook.com/groups/keepingabreastwdrjennConnect with Dr. Jenn:Website: https://www.realhealthmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

This week's episode has our host feeling a tad out of his element while interviewing three powerhouse professionals about Women, Work, and Wholeness. So, he takes the more polite approach rather than a pushy one. Chris Boehlke, who put the “Bo” in Bospar as the PR agency's principal, shares wisdom gleaned from her years in the communications industry and explains how “wholeness” is not all about multitasking but focusing on self-care in addition to the well-being of others. She recounted when job interviewers asked women if they planned to have kids, potentially hindering their ability to travel for business, and how far we've come today with considerations for working moms. She had these women in mind when co-founding an entirely remote PR agency in pre-pandemic times. She's joined by Jane King, Founder of LilaMax Media (named after her children) and business journalist of over two decades, who can be seen reporting live from the NASDAQ. Jane, who wakes up at an astonishingly early hour daily, discusses the importance of focusing on excellence rather than perfection, planning, enjoying weekends, and having dinners together as a family. She surprises the panel by disclosing the amenity she has unbelievable constant access to but still can't seem to make time for. Johanna Lucas, who hails from Genentech and is now executive director of talent acquisition at BioMarin Pharmaceutical, joins the panel. She discusses caring and being attentive to one's mind, body and spirit simultaneously, rather than having to play catchup when one of those is neglected for another. She also responds to Chris's thoughts on the importance of self-care for women to feel whole. Listen to our host be humbled as he's told, “We know more about being women than you do!”

On this episode of CISO to CISO we would like to welcome Chris Houlder, Head of Global CyberSecurity at BioMarin Pharmaceutical Inc. With nearly 25 years of experience spanning information security, team management, information technology and product/software security, Chris has been developing and executing strategies to solve complex security challenges and leading operational and company changes. Previously, Chris served as CISO and lead teams at Clarivate Analytics and Autodesk. Chris current serves as a board member for Rapticore, also a venture advisor for YL Ventures.

Deemed a Top 40 Healthcare Transformer by Medical Marketing & Media, Sandra Shpilberg is the CEO of the digital patient-finding platform SeekerHealth, which she founded in 2015. Sandra was no stranger to the medical field when she launched her successful brand, previously working in the biopharmaceutical space as Vice President of Commercial Development and Strategic Marketing for Nora Therapeutics as well as Executive Director at BioMarin Pharmaceutical. Additionally, Sandra is the best-selling author of New Startup Mindset: 10 Mindset Shifts to Build the Company of Your Dreams.   Today, Sandra joins me to highlight insights from her book New Startup Mindset, which discusses the lessons learned through her journey of founding and leading SeekerHealth. Sandra shares how she approached this entrepreneurial venture, the two types of difficulties we face as founders, and insights into the exit process. Sandra also discussed whether inspiration is necessary for creation, why it is crucial to address burnout as an entrepreneur, and the importance of prioritizing mindset and personal growth as a founder.   “There really is no way to create new things if you’re not pushing yourself to be a beginner.” - Sandra Shpilberg   Today on When She Founded: How the lessons in Sandra’s book New Startup Mindset helped her succeed with her book launch Sandra’s career journey and the myths she busted as she launched SeekerHealth The problem that Sandra set out to solve through her brand and how she found the conviction to pursue her vision Why clinical trials are so important in the eyes of patients and the current focus for most clinical trials The importance of inner mindset and how Sandra intervened with her inner critic The value of a professional network and how Sandra found her early customers Stumbling points along her entrepreneurial journey and what Sandra learned through these struggles The impact of burn out, how long it takes to recover from it, and the importance of honoring your body’s needs Why you shouldn’t wait to resolve your pain before you begin creating The difference between a vacation and a retreat, and why you should retreat rather than quit What mindfulness truly is and how it applies to business How Sandra’s personal experience with immigration has fueled her career journey Connect with Sandra Shpilberg: Sandra Shpilberg Sandra Shpilberg on LinkedIn Sandra Shpilberg on Facebook Sandra Shpilberg on Instagram Sandra Shpilberg on Twitter New Startup Mindset: 10 Mindset Shifts to Build the Company of Your Dreams by Sandra Shpilberg   Subscribe, Rate & Share Your Favorite Episodes! Thanks for tuning into today’s episode of When She Founded with your host, Somer Hamrick. If you enjoyed this episode, please head over to Apple Podcasts to subscribe and leave a rating and review. Don’t forget to visit our website, connect with Somer on LinkedIn, and share your favorite episodes across social media.

In this episode, AOP Host Philip Ideson and Kelly Barner (AOP Content Director and Owner of Buyers Meeting Point) discuss their major take-aways from August’s news, industry topics and podcast interviews. In August, we split our time between active procurement practitioners and thought leaders. Dana Small, Global Category Manager at BioMarin Pharmaceutical, talked about her transition from finance to procurement (yes, on purpose) and shared how being a business blogger changes her perspective on her ‘day job’. Then Jason Cammorata, Vice President of Strategic Sourcing at MDC Partners, spoke about the qualities that make conflict “good” for an enterprise and the teams within it. On the thought leader side, Hélène Laffitte, Founder and CEO of Consulting Quest, provided insight into best practices for sourcing consulting services and Procurement Insights Founder Jon Hansen pointed out that while companies can’t transform without going through procurement and supply chain, we aren’t alone in the disruptive challenges we face. This month’s discussion topic is technology implementation ‘turn arounds’. Since implementations rarely go smoothly without considerable planning and communication, something both Philip and Kelly have experienced personally, nearly every implementation needs a turn around. Often, this stems from the misplaced expectation that implementation = digital transformation, and vice versa.

It was the best Mob movie I’ve seen in a long time. Michael Cohen testified before Congress and it was large-popcorn-bucket-worthy. Like we’ve been saying for a couple of years now, the best way to understand the Trump administration is to read it as an organized crime story. Now it looks like we’re going to get Trump’s accountant, Allen Weisselberg, to testify after all. Cohen’s closing statement warned that if Trump loses the 2020 election, he will not allow for a peaceful transfer of power. Trump got Kim Jong Un-ed in Vietnam. Pramila Jayapal drops a major Medicare for All bill that - wait for it - is better than the plan advocated for by Bernie Sanders. The bill was drafted with nurses, doctors, disability rights advocates, advocates for the elderly, and organizations such as Public Citizen and the Center for Popular Democracy. This past Tuesday was a great day for Chicago socialists as 4 of the 5 DSA endorsed candidates won their election to Chicago’s city council. At least two other progressives also ousted established Democratic Party Machine candidates. Washington Gov. Jay Inslee enters the presidential race with an unabashed commitment to address the climate crisis. CPAC is underway just outside DC. All the tensions with Trump are nowhere to be found as the right-wing political conference fully embraces MAGA. And if you wanted to know if progressive/left policies are moving the needle, look no further than right-wing ex-Senator Rick Santorum who went to CPAC calling for paid family leave. Charter Appeals Board??? Say what?  Imagine a state-controlled government panel that is specifically designed to overturn local school boards and favor charter schools. About 1,700 workers are on strike in Erie, PA as Wabtec, the new owners of the former GE locomotive plant, demanded up to 38% reduction in wages, mandatory overtime, expanded use of temps, and arbitrary scheduling. Bernie Sanders weighed in on the strike saying, "The American people are sick and tired of corporate America and their wealthy CEOs ripping off the working families of this country.” In These Times has called this the “biggest U.S. manufacturing strike in the Trump era.” Senator Bob Casey says he will be backing a $15/hour federal minimum wage bill, marking his continued political evolution. PA House GOP Candidate Frank Scavo is a Pizzagate conspiracy theorist who is running for an open house seat in Lackawanna County.  It’s been a Democratic stronghold for decades but voted for Trump in 2016. Big Pharma, Big Greed. A PA woman used to be able to get for free medication for a rare neuromuscular disease. But thanks to BioMarin Pharmaceutical who recently gained exclusive rights to see the drug, she is facing a $375,000/year bill. Her case is one of the thousands like it that has been the subject of hearings in DC. Elections have consequences. State Senator Vincent Hughes wants to "take a data-driven approach to public policy to ensure that lawmakers are fully informed of the potential impacts of legislation on people living in poverty before they vote." In today’s Last Call, Space X set to test its first-ever Crew Dragon Spacecraft tomorrow if the weather continues to cooperate. The Crew Dragon is designed to bring astronauts to the International Space Station. If all goes well, this will be the first “crew-capable orbital spacecraft” to launch from the U.S. since the Obama administration scrapped the space shuttle program in 2011 in favor of contracting out missions to the ISS. Boeing, the other company tapped by NASA to fly crewed missions to the ISS has its own test launch set for April. Canada is the first country to join up to support NASA’s lunar gateway project. The Lunar Orbital Platform Gateway program will be a human-tended facility in orbit around the moon, kind of like a sister station to the ISS. This Sunday, Free Will Brewing will be celebrating the “Spirit of Mardi Gras” with a barrel aged tap takeover at the main brewery in Perkasie. Plus, a double can release tomorrow: Fresh King Cake  - a No Boil White Ale brewed with 120 pounds of fresh ground pecans, orange, cinnamon, and vanilla. 7% ABV. Saturday can and draft release, March 2nd! 7 Course Red - just in time for St Patty's Day prep, it's Free Will's traditional Irish Red Ale, malt forward with notes of toffee, toasted bread, and dried fruit. Brewed with a touch of roasted barley and carared for additional color and a beautiful tan head.

Dr. Todd Zankel is co-founder and Chief Scientific Officer of Mercaptor Discoveries, Inc., a biotech company focused on developing molecules to treat brain injury and degeneration. Todd studies chemistry and molecular biology to develop new drugs to treat diseases of the central nervous system and brain. The molecules they are working on now help reduce side effects by making drugs only active in the parts of the body they are supposed to target. When he’s not working, Todd likes to read non-science books and take his dog for walks in the hills and woods near his house. Todd received his B.A. in Chemistry from Reed College and his Ph.D. in Chemistry from Columbia University. Afterwards, he accepted a position as an NIH postdoctoral fellow at the Plant Gene Expression Center in Berkeley, California as well as the Chemistry Department of ETH in Zurich, Switzerland. Todd then worked for BioMarin Pharmaceutical for about eight years. Before co-founding Mercaptor Discoveries, Todd co-founded Raptor Pharmaceuticals in 2006, acting as Chief Scientific Officer and head of discovery research until 2016 when the company was acquired. In our interview, Todd shared more about his life and science.

Today in FirstWord:

1) Low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study2) What's Trending: Interview with Dafne Horovitz about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection3) Topic of the month: Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Andy Southerland about his paper on a low-cost, tablet-based option for prehospital neurologic assessment. Dr. Ted Burns is interviewing Dr. Dafne Horovitz for our “What's Trending” feature of the week about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection. Dr. Alberto Espay interviews Drs. Dave Knopman and Kaycee Sink about their Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publications of the books Stroke and Neurology in Practice [Edited book]; and receives research support from the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Horovitz serves as Associate Editor for Journal of Community Genetics; received speaker honoraria from Biomarin Pharmaceutical, Genzyme-Sanofi, Shire Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc.; received funding for travel to medical meeting from Genzyme-Sanofi and Shire Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Knopman serves on the scientific advisory board for Consultant Bluefield project, Lundbeck Pharmaceuticals Inc., DIAN study DSMB; served as Associate Editor for Neurology® until October 2015; receives research support from the NIH, Mayo Alzheimer's Disease Research Center, Mayo Alzheimer Disease Patient Registry, ARIC Dementia Study and Chronic Kidney Disease and Cognitive functioning; received funding for travel to two lectures Alzheimer Conference, Seoul Korea and Behavioral Neurology Conference, Hyderabad, India.Dr. Sink served on the data safety monitoring board for two NIH funded clinical trials; initiated grants from the Alzheimer's Association and the Donald W. Reynolds Foundation as an investigator; received research support from the NIH.

Today in FirstWord:

Today in FirstWord: